Genitourinary Syndrome of Menopause – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of GSM comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of GSM for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s GSM forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GSM over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts seven GSM patient populations, as follows:
- Total GSM prevalent cases
- Total GSM prevalent cases with stress urinary incontinence
- Total GSM prevalent cases with dysuria
- Total GSM prevalent cases with symptomatic pelvic organ prolapse
- Total GSM prevalent cases with fecal incontinence
- Total GSM prevalent cases with urinary frequency
- Total GSM prevalent cases with urgency urinary incontinence
Note: coverage may vary by country.
